# First-in-Human Implantable Lymphatic Micropump Demonstrates Safety and Efficacy in Breast Cancer-Related Lymphedema

> clinical trial · REPORTED · 2025-05-01

Researchers at Lausanne University Hospital published first-in-human pilot study results for the LymphoPilot device, an implantable subcutaneous catheter and micropump system designed to actively replicate lymphatic vessel function, showing safety, efficacy, and significant limb volume reductions in nine breast cancer-related lymphedema patients without conventional decongestive therapies. Promising results were deemed to warrant further research into long-term use.

About LymphoPilot (CHUV Lausanne): LymphoPilot is a first-of-its-kind implantable medical device developed at CHUV Lausanne that uses subcutaneous catheters and a micropump to actively manage lymphatic fluid in patients with lymphedema, targeting the unmet need of breast cancer survivors who develop secondary lymphedema after cancer treatment.

- Company: LymphoPilot (CHUV Lausanne)
- Sector: medical devices
- Primary source: https://www.sciencedirect.com/science/article/abs/pii/S0953620525000378

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.